secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0000950170-23-007709
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo achieves target enrollment in Phase 2b STRIDE trial of mavodelpar; topline Q4 2023
--------------------------------------------------------------------------------

- Target enrollment reached in global STRIDE study for mavodelpar in adult PMM patients.
- STRIDE AHEAD long-term safety trial amended to enroll PMM due to mtDNA and nuclear DNA defects.
- Topline data from STRIDE expected in Q4 2023; marketing applications planned for 2024.
- STRIDE is a randomized, double-blind, placebo-controlled Phase 2b trial of 100 mg mavodelpar daily.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023007709/0000950170-23-007709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017023007709/rphm-20230314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer